 | Exhibitor booth at the American Society of Haemotology
(ASH) 2006 Annual Meeting in Orlando, FL. |
A Phase I/II Study of Arsenic Trioxide, Bortezomib,
and Ascorbic Acid in Relapsed or Refractory Multiple Myeloma
Presented at ASCO 2006
Click here to download the results of this study
Phase I Study of Bortezomib and 153SM-lexidronam
Combination for Refractory and Relapsed Multiple Myeloma
Presented at ASCO 2006
Click here to download the results of this study
Phase I Study of Zio-101: a Novel Organic Arsenic Active
in Acute Myelogenous Leukemia (AML) and Multiple Myeloma (MM)
Presented at ASH 2006
Click here to download the results of this study
Phase I Study of Bortezomib and 153SM-lexidronam
Combination for Refractory and Relapsed Multiple Myeloma
Presented at ASH 2006
Click here to download the results of this study
|
